Australia's Bionomics falls after drug fails to meet primary endpoint of study

Bionomics

19/12/2022 01:13

** Shares of Australia's Bionomics Ltd  BNO.AX  fall as much
as 38.6% to A$0.035 - set to mark their worst day since June 26
,2019, if losses hold 
    ** Stock hits lowest since April 3, 2020
    ** Biopharma co says its drug BNC210 did not meet primary
endpoint for PREVAIL Phase 2 Study 
    ** BNC210 is used for treatment of Social Anxiety Disorder
(SAD) 
    ** "Although the PREVAIL study did not statistically meet
its primary endpoint, we have noted the consistent trends in
improvement of endpoints exibited by the drug "- Co 
    ** Stock has fallen 48.2% this year as of last close
 (Reporting by Nausheen Thusoo in Bengaluru)
 ((Nausheen.Thusoo@thomsonreuters.com))